Special Issue

Personalized Surgical Management of Genito-Urinary Cancers

Message from the Guest Editor

The surgical management of genito-urinary (GU) cancers has seen much development over the last decades. Novel treatment approaches are gaining space and interest, moving from mini-invasive surgery and robotic platforms spreading to organ-sparing treatments and multimodality. Today, surgical stress and invasiveness are progressively reducing, moving progressively to single-port and extraperitoneal approaches to manage prostate and kidney cancers. At the same time robotics, digital endourology and laser improvements are changing scenarios in urothelial cancers. The introduction of machine learning and artificial intelligence are awaited to add information and integrated surgical procedures. Moreover, a new attention to the quality of life, precise surgical patient selection and early recovery have similarly gained popularity in clinical practice, with a renewed focus on personalized interventions and reduced morbidity. This Special Issue presents up-to-date summaries regarding the personalized surgical management of GU cancers and the development of patient-centered management from preoperative, intraoperative and postoperative aspects.

Guest Editor

Dr. Nazario Foschi

Department of Urology, "Agostino Gemelli" Academic Hospital Foundation, IRCCS, Catholic University School of Medicine, Rome, Italy

Deadline for manuscript submissions

15 December 2024



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/202951

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

